Effectiveness and safety of pyrotinib‐based therapy in patients with HER2‐positive metastatic breast cancer: A real‐world retrospective study
Abstract The previous studies had demonstrated the promising effectiveness and acceptable safety of pyrotinib in patients with HER2‐positive metastatic breast cancer. We aimed to investigate the real‐world data of pyrotinib in complex clinical practice and complement the findings of clinical trials....
Enregistré dans:
Auteurs principaux: | Chao Li, Xiaoli Bian, Zhaoyun Liu, Xinzhao Wang, Xiang Song, Wei Zhao, Yansong Liu, Zhiyong Yu |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Wiley
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/357c177e18c045569d6a81b2ad610d5a |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
par: Board Editorial
Publié: (2021) -
The tumor immune microenvironment of primary and metastatic HER2− positive breast cancers utilizing gene expression and spatial proteomic profiling
par: Ilana Schlam, et autres
Publié: (2021) -
Metastatic breast cancer: Endocrine therapy landscape reshaped
par: Mohamad Adham Salkeni, et autres
Publié: (2017) -
Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments
par: Serafin Morales, et autres
Publié: (2021) -
HER2/neu Status in Breast Cancer Specimens: Comparison of Immunohistochemistry (IHC) and Fluorescence in situ Hybridization (FISH) Methods
par: Saglican,Yesim, et autres
Publié: (2015)